Merck
  • Home
  • Search Results
  • Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.

Journal of the National Cancer Institute (2014-06-14)
Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, Garth D Nelson, Steven R Alberts, Frank A Sinicrope, Richard M Goldberg, Paul J Limburg, Stephen N Thibodeau, Axel Grothey, Joleen M Hubbard, Emily Chan, Suresh Nair, Jeffrey L Berenberg, Robert R McWilliams
ABSTRACT

KRAS and BRAF (V600E) mutations are important predictive and prognostic markers, respectively, in colon cancer, but little is known about patient and clinical factors associated with them. Two thousand three hundred twenty-six of 3397 patients in the N0147 phase III adjuvant trial for stage III colon cancer completed a patient questionnaire. Primary tumors were assessed for KRAS and BRAF (V600E) mutations and defective mismatch repair (dMMR) status. Logistic regression models and categorical data analysis were used to identify associations of patient and tumor characteristics with mutation status. All statistical tests were two-sided. KRAS (35%) and BRAF (V600E) (14%) mutations were nearly mutually exclusive. KRAS mutations were more likely to be present in patients without a family history of colon cancer and never smokers. Tumors with KRAS mutations were less likely to have dMMR (odds ratio [OR] = 0.21; 95% confidence interval [CI] = 0.15 to 0.31; P < .001) and high-grade histology (OR = 0.73; 95% CI = 0.59 to 0.92; P < .001) but were more often right-sided. Among KRAS-mutated tumors, those with a Gly13Asp mutation tended to have dMMR and high-grade histology. Tumors with BRAF (V600E) mutations were more likely to be seen in patients who were aged 70 years or older (OR = 3.33; 95% CI = 2.50 to 4.42; P < .001) and current or former smokers (OR = 1.64; 95% CI = 1.26 to 2.14; P < .001) but less likely in non-whites and men. Tumors with BRAF (V600E) mutations were more likely to be right-sided and to have four or more positive lymph nodes, high-grade histology, and dMMR. Specific patient and tumor characteristics are associated with KRAS and BRAF (V600E) mutations.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glycine, ACS reagent, ≥98.5%
Sigma-Aldrich
L-Aspartic acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
L-Valine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-Aspartic acid, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Valine, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
L-Aspartic acid, BioUltra, ≥99.5% (T)
Sigma-Aldrich
Glycine, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
Sigma-Aldrich
Glycine, BioUltra, for molecular biology, ≥99.0% (NT)
Supelco
Glycine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
Sigma-Aldrich
Glycine, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Sigma-Aldrich
Glycine, tested according to Ph. Eur.
SAFC
L-Aspartic acid
SAFC
L-Valine
SAFC
Glycine
Sigma-Aldrich
L-Glutamic acid hydrochloride, ≥99% (HPLC)
Sigma-Aldrich
L-Valine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Glycine, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glycine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
L-Aspartic acid, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
Glycine, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Glycine, BioXtra, ≥99% (titration)
Sigma-Aldrich
Glycine, 99%, FCC
Supelco
Glycine, analytical standard, for nitrogen determination according to Kjeldahl method
Supelco
L-Valine, certified reference material, TraceCERT®
Sigma-Aldrich
DL-Aspartic acid, ≥99% (TLC)
Supelco
Glycine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Aspartic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Glutamic acid, European Pharmacopoeia (EP) Reference Standard
Glycine, European Pharmacopoeia (EP) Reference Standard
Aspartic acid, European Pharmacopoeia (EP) Reference Standard